专利检索 ap:("Novartis AG") AND inv:"Stefan DE BUCK" 第 1 页

1.

发明申请
METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING A BRUTON'S TYROSINE KINASE INHIBITOR 有权

公开(公告)号：US20220184074A1

公开(公告)日：2022-06-16

申请号：US17612778

申请日：2020-05-20

申请人： NOVARTIS AG

发明人： Souvik BHATTACHARYA , Bruno BIETH , Maciej CABANSKI , Bruno CENNI , Stefan DE BUCK , Martin KAUL , Arvind KINHIKAR , Andrijana RADIVOJEVIC , Thomas SEVERIN , Julian STORIM , Alessandra VITALITI GARAMI

IPC分类号： A61K31/505 , A61P17/00

摘要： The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

2.

发明申请
USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJOGREN'S SYNDROME 审中-公开

公开(公告)号：US20190038628A1

公开(公告)日：2019-02-07

申请号：US16075066

申请日：2017-02-10

申请人： Novartis AG

发明人： Bruno BIETH , Christoph BURKHART , Andreas CHRIST , Stefan DE BUCK , Christoph KALIS , Sam LINDGREN

IPC分类号： A61K31/519 , A61P37/00

摘要： The invention relates to the use of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one or pharmaceutically acceptable salts thereof for the treatment of primary Sjögren's Syndrome.

3.

发明申请
METHODS OF TREATING SJOGREN'S SYNDROME USING A BRUTON'S TYROSINE KINASE INHIBITOR 有权

公开(公告)号：US20220175772A1

公开(公告)日：2022-06-09

申请号：US17612737

申请日：2020-05-20

申请人： NOVARTIS AG

发明人： Souvik BHATTACHARYA , Bruno BIETH , Maciej CABANSKI , Bruno CENNI , Stefan DE BUCK , Martin KAUL , Arvind KINHIKAR , Andrijana RADIVOJEVIC , Alessandra VITALITI GARAMI

IPC分类号： A61K31/505 , A61P37/06 , A61P1/02

摘要： The present disclosure relates to methods for treating Sjögren's Syndrome disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Sjögren's Syndrome patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.